Sign Out
Metastatic Breast Cancer (MBC): Vivitra is indicated for the treatment of patients with HER2 overexpressing metastatic breast cancer.
Vivitra is also indicated in combination with aromatase inhibitor for the treatment of patients with HER2 overexpressing and hormone receptor-positive metastatic breast cancer.
Early Breast Cancer (EBC): Vivitra is indicated for the treatment of patients with HER2 overexpressing early breast cancer following surgery, chemotherapy (neo adjuvant or adjuvant) and radiotherapy (if applicable).
Vivitra is also indicated for adjuvant treatment of patients with HER2 overexpressing node positive or node negative breast cancer i) as part of treatment regimen comprising doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel ii) with docetaxel and carboplatin.
Metastatic Gastric Cancer (MGC): Vivitra is indicated for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in combination with capecitabine or 5-fluorouracil and cisplatin who have not received prior anti-cancer treatment for their metastatic disease.
